Story perspectives

FDA Advances Drug Trials, Embraces AI to Reduce Testing

9/3/2025

Summary

Story summary

The FDA will hold a Type A meeting regarding the complete response letter for vusolimogene oderparepvec plus nivolumab due to insufficient effectiveness evidence from the IGNYTE trial.
AVZO-103 has been approved for a first-in-human trial focused on solid tumors, evaluating safety and initial activity.
An End of Phase 2 meeting for OST-HER2 revealed no major safety issues, facilitating its upcoming Biologics License Application (BLA) submission.
The FDA intends to decrease animal testing by utilizing AI technologies to accelerate drug development and reduce costs.

1 of 1

Story summary

The FDA will hold a Type A meeting regarding the complete response letter for vusolimogene oderparepvec plus nivolumab due to insufficient effectiveness evidence from the IGNYTE trial.
AVZO-103 has been approved for a first-in-human trial focused on solid tumors, evaluating safety and initial activity.
An End of Phase 2 meeting for OST-HER2 revealed no major safety issues, facilitating its upcoming Biologics License Application (BLA) submission.
The FDA intends to decrease animal testing by utilizing AI technologies to accelerate drug development and reduce costs.